Payment overview · 2025
General Payments
$566.87
29 reported records · 15 companies
Healthcare provider profile · identity verified
Khalid Mohammed Ahmed, MD
Allopathic & Osteopathic Physicians|Internal Medicine · FLINT, MI · NPI 1619965175
Verified facts
What the public records show
CMS Open Payments records show Khalid Mohammed Ahmed, MD received $566.87 in general payments during 2025 across 29 reported records.
Vanda Pharmaceuticals Inc. accounted for 20.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $114.46 | 20.2% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $95.96 | 16.9% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $73.81 | 13.0% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $52.47 | 9.3% | 3 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $36.62 | 6.5% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $32.04 | 5.7% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $26.00 | 4.6% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $22.88 | 4.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $22.17 | 3.9% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $19.86 | 3.5% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $17.04 | 3.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.67 | 2.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.13 | 2.5% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $13.76 | 2.4% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $10.00 | 1.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $553.11 | 28 |
| Education | $13.76 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $114.46 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $93.67 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $70.56 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $52.47 | 3 | 2025 |
Source payment records
|
|||||
| COLLAGENASE SANTYL Normalized: collagenase santyl |
Drug | Smith+Nephew, Inc. | $36.62 | 2 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $32.04 | 2 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $26.00 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $25.40 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $25.40 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $22.88 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $22.17 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $17.04 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.67 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.13 | 1 | 2025 |
Source payment records
|
|||||
| EOHILIA Normalized: eohilia |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $13.76 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $10.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
105 | 28 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
12 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 291 | 93 |
| Amlodipine Besylate | Amlodipine Besylate | 290 | 89 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 224 | 88 |
| Losartan Potassium | Losartan Potassium | 145 | 45 |
| Levothyroxine Sodium | Levothyroxine Sodium | 142 | 30 |
| Furosemide | Furosemide | 141 | 46 |
| Metoprolol Tartrate | Metoprolol Tartrate | 141 | 49 |
| Metformin Hcl | Metformin Hcl | 137 | 49 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 115 | 40 |
| Omeprazole | Omeprazole | 113 | 47 |
| Clopidogrel | Clopidogrel Bisulfate | 105 | 31 |
| Eliquis | Apixaban | 105 | 28 |
| Lisinopril | Lisinopril | 103 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 85 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 74 | 37 |
| Gabapentin | Gabapentin | 73 | 31 |
| Sertraline Hcl | Sertraline Hcl | 62 | 31 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 61 | 16 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 59 | 18 |
| Potassium Chloride | Potassium Chloride | 58 | 21 |
| Metoprolol Succinate | Metoprolol Succinate | 57 | 22 |
| Trazodone Hcl | Trazodone Hcl | 55 | 20 |
| Meloxicam | Meloxicam | 51 | 26 |
| Levetiracetam | Levetiracetam | 49 | 12 |
| Promethazine Hcl | Promethazine Hcl | 49 | 25 |
| Naproxen | Naproxen | 46 | 20 |
| Hydralazine Hcl | Hydralazine Hcl | 43 | 16 |
| Donepezil Hcl | Donepezil Hcl | 41 | 17 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 41 | 16 |
| Nifedipine Er | Nifedipine | 40 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 40 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 34 |
| Famotidine | Famotidine | 38 | 11 |
| Allopurinol | Allopurinol | 37 | 13 |
| Pantoprazole Sodium | Pantoprazole Sodium | 37 | 19 |
| Simvastatin | Simvastatin | 36 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 36 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 35 | suppressed |
| Ibuprofen | Ibuprofen | 34 | 20 |
| Tramadol Hcl | Tramadol Hcl | 33 | 12 |
| Finasteride | Finasteride | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | 12 |
| Carvedilol | Carvedilol | 31 | 15 |
| Glipizide | Glipizide | 29 | suppressed |
| Memantine Hcl | Memantine Hcl | 29 | suppressed |
| Baclofen | Baclofen | 28 | suppressed |
| Prednisone | Prednisone | 28 | 12 |
| Alprazolam | Alprazolam | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | suppressed |
| Atenolol | Atenolol | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | 15 |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 24 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | 11 |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 22 | suppressed |
| Lactulose | Lactulose | 22 | suppressed |
| Nystatin | Nystatin | 22 | 13 |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Entresto | Sacubitril/Valsartan | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Ozempic | Semaglutide | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 19 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 19 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 19 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 18 | suppressed |
| Lacosamide | Lacosamide | 18 | suppressed |
| Ranolazine Er | Ranolazine | 18 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 12 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Azithromycin | Azithromycin | 16 | 16 |
| Megestrol Acetate | Megestrol Acetate | 16 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 14 | suppressed |
| Jardiance | Empagliflozin | 14 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 12 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 11 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Insulin Lispro | Insulin Lispro | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
| Sulfasalazine | Sulfasalazine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $566.87 · 29 records | Vanda Pharmaceuticals Inc. | Auvelity, BREZTRI, CAPLYTA, COBENFY, COLLAGENASE SANTYL, Dexcom G6 Transmitter, EOHILIA, FANAPT, QULIPTA, REXULTI, TRELEGY ELLIPTA, TZIELD, UBRELVY, UZEDY, VRAYLAR, Wegovy | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error